规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) 是一种抗白血病和免疫抑制剂,可作为 SARS 和 MERS 冠状病毒木瓜蛋白酶 (PLpros) 的抑制剂,还可有效抑制 USP2 活性,IC50 为 25 Pproros 和重组人 USP2 分别为 μM 和 40 μM[1]。 6-硫鸟嘌呤 (Thioguanine) 通过纯化的 DNA 甲基转移酶(包括人 DNMT1 和细菌 HpaII 甲基化酶)影响胞嘧啶残基的甲基化。 6-硫鸟嘌呤 (Thioguanine)(1 或 3 μM)可降低 Jurkat T 细胞中的整体胞嘧啶甲基化,并在 3 μM 时降低人类细胞中的胞嘧啶甲基化[2]。 6-硫鸟嘌呤 (Thioguanine)(18.75、37.50 或 75.00 μM)显着影响细胞活力,但对 LDH 或 ALT 活性没有影响[3]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
在异种移植模型中,硫鸟嘌呤在选择性杀死 BRCA2 缺陷型肿瘤方面与 PARP 抑制剂一样有效。 6-硫鸟嘌呤可有效杀死此类 BRCA1 缺陷型 PARP 抑制剂耐药肿瘤。 6-硫鸟嘌呤可以杀死通过 BRCA2 基因的遗传逆转而对 PARP 抑制剂或顺铂产生耐药性的细胞和肿瘤
|
||
动物实验 |
|
||
参考文献 |
[1]. Chuang SJ, et al. 6-Thioguanine is a noncompetitive and slow binding inhibitor of human deubiquitinating protease USP2. Sci Rep. 2018 Feb 15;8(1):3102.
[2]. Wang H, et al. 6-Thioguanine perturbs cytosine methylation at the CpG dinucleotide site by DNA methyltransferases in vitro and acts as a DNA demethylating agent in vivo. Biochemistry. 2009 Mar 17;48(10):2290-9. [3]. LaDuke KE, et al. Effects of azathioprine, 6-mercaptopurine, and 6-thioguanine on canine primary hepatocytes. Am J Vet Res. 2015 Jul;76(7):649-55 |
分子式 |
C5H5N5S
|
---|---|
分子量 |
167.1917
|
CAS号 |
154-42-7
|
SMILES |
S=C1NC(N)=NC2=C1NC=N2
|
InChi Key |
WYWHKKSPHMUBEB-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
|
化学名 |
2-amino-1H-purine-6(7H)-thione
|
别名 |
2-Amino-6-purinethiol; thioguanine; ThioguanineTabloid; Tioguanine. Lanvis; Tioguanin; 6TG; TG. BW 5071; WR1141; X 27.
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO : ~10 mg/mL (~59.81 mM)
|
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 5.9812 mL | 29.9061 mL | 59.8122 mL | |
5 mM | 1.1962 mL | 5.9812 mL | 11.9624 mL | |
10 mM | 0.5981 mL | 2.9906 mL | 5.9812 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00002944 | Completed | Drug: carboplatin Drug: lomustine |
Brain Tumors Central Nervous System Tumors |
Children's Oncology Group | April 1997 | Phase 3 |
NCT02912676 | Completed | Drug: Thioguanine (oral) | Acute Lymphoblastic Leukemia | Kjeld Schmiegelow | October 2016 | Phase 1 Phase 2 |
NCT00587873 | Completed | Drug: Leucovorin calcium Drug: 6-Thioguanine |
Hodgkin's Disease | Memorial Sloan Kettering Cancer Center |
March 1994 | Phase 2 |
NCT05276284 | Recruiting | Combination Product: Atezolizumab, 6-mercaptopurine, 6-thioguanine |
Solid Tumor, Adult Metastatic Cancer |
Kristoffer Rohrberg | September 1, 2022 | Phase 1 Phase 2 |
Time-dependent inactivation of USP2 by 6TG. (A) Different concentrations of 6TG (0 μM, closed circles; 10–100 μM, open circles) were incubated with USP2 and enzyme activity was measured for 200 s. Across all trials, Ub-AFC concentration was held at 0.5 μM and USP2 concentration was held at 0.2 μM. The solid lines show the best fit results when the data was fitted to the slow-binding equation. (B) The observed inactivation rate constants (kinact) from panel A were replotted against 6TG concentrations. The solid line represents the best fit of the data to the saturation equation. The apparent Kinact value is shown in Table 1. td> |
Comparison with other structures of human USP2. Overlay of the active site of human USP2-Ub complex (grey; PDB code: 2hd5) with that of USP2-Ub-6TG complex (USP2: cyan; Ub: yellow; 6TG: orange) (A) or that of USP2 C276S mutant (green) in complex with Ub (magenta) (B). The dashed lines show hydrophilic interactions. The arrow in panel (A) indicates the movement of residue Asp575, while that in panel (B) shows the side-chain movement of residue 276, which has been mutated from cysteine to serine. td> |
6-Thioguanine treatment results in decreased cytosine methylation in human cells. Plotted are the percentages of global cytosine methylation in genomic DNA isolated from Jurkat T cells that were untreated or treated with SG or 5-aza-dC. The data represent the means and standard deviations of results from three independent drug treatments and HPLC measurements. The P values were calculated by using paired t-test. td> |